Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Acute promyelocytic leukemia other imaging studies
Introduction
Overview
Overview
Additional imaging studies that can be useful in acute promyelocytic leukemia include echocardiogram, chest X-ray, and brain MRI.
Acute promyelocytic leukemia other imaging findings
Acute promyelocytic leukemia other imaging findings
- Echocardiogram:
- An echocardiogram is an essential imaging modality in patients with acute promyelocytic leukemia receiving anthracycline chemotherapy.[1]
- Patients who will be receiving anthracycline-based therapy require a baseline echocardiogram to assess the ejection fraction prior to therapy.[2]
- Anthracyclines are known to cause cardiac toxicity (specifically cardiomyopathy with cumulative anthracycline doses above 500mg/m2).[3]
- An echocardiogram should be obtained every three months while on therapy with anthracycline. Echocardiogram applies particularly to cases of high-risk acute promyelocytic leukemia, in which case the standard of care is to give anthracycline along with all-trans retinoic acid.[4]
- Chest X-ray:
- Chest radiography is useful in the assessment of differentiation syndrome, which is a therapy-related complication when patients are treated with all-trans retinoic acid. Chest X-ray will show pulmonary infiltrate and/or edema.[5]
- MRI of the brain:
- In rare cases, acute promyelocytic leukemia can present with central nervous system deficits.[6]
- MRIs of the brain is a useful to assess for lesions of the gray or white matter. MRIs of the brain should be done if a patient has neurological deficits.
References
References
- ↑ Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA; et al. (2012). “Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines”. Am J Cardiol. 110 (11): 1679–86. doi:10.1016/j.amjcard.2012.07.040. PMC 3496816. PMID 22917553.
- ↑ McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM (February 2017). “Anthracycline Chemotherapy and Cardiotoxicity”. Cardiovasc Drugs Ther. 31 (1): 63–75. doi:10.1007/s10557-016-6711-0. PMC 5346598. PMID 28185035.
- ↑ Rahman AM, Yusuf SW, Ewer MS (2007). “Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation”. Int J Nanomedicine. 2 (4): 567–83. PMC 2676818. PMID 18203425.
- ↑ Avvisati, G.; Lo-Coco, F.; Paoloni, F. P.; Petti, M. C.; Diverio, D.; Vignetti, M.; Latagliata, R.; Specchia, G.; Baccarani, M.; Di Bona, E.; Fioritoni, G.; Marmont, F.; Rambaldi, A.; Di Raimondo, F.; Kropp, M. G.; Pizzolo, G.; Pogliani, E. M.; Rossi, G.; Cantore, N.; Nobile, F.; Gabbas, A.; Ferrara, F.; Fazi, P.; Amadori, S.; Mandelli, F. (2011). “AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance”. Blood. 117 (18): 4716–4725. doi:10.1182/blood-2010-08-302950. ISSN 0006-4971.
- ↑ Xu LM, Zheng YJ, Wang Y, Yang Y, Cao FF, Peng B; et al. (2014). “Celastrol inhibits lung infiltration in differential syndrome animal models by reducing TNF-α and ICAM-1 levels while preserving differentiation in ATRA-induced acute promyelocytic leukemia cells”. PLoS One. 9 (8): e105131. doi:10.1371/journal.pone.0105131. PMC 4130635. PMID 25116125.
- ↑ Montesinos P, DÃaz-Mediavilla J, Debén G, Prates V, Tormo M, Rubio V; et al. (2009). “Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis”. Haematologica. 94 (9): 1242–9. doi:10.3324/haematol.2009.007872. PMC 2738716. PMID 19608685.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2], Sogand Goudarzi, MD [3]; Grammar Reviewer: Natalie Harpenau, B.S.[4]